22.8 C
New York
Saturday, May 28, 2022

Japanese beta-glucan improves behavior, sleep, and gut microbiome in clinical study in children with autism spectrum disorder

- Advertisement -
- Advertisement -

Controlling enterobacteria, one of the causes of the disease, can help fight Parkinson’s and Alzheimer’s

TOKYO, March 14, 2022–(BUSINESS WIRE)–In the first report of its kind, children with autism spectrum disorder (ASD) showed improvements in behavior, learning and sleep after Black yeast strain AFO-202 Aureobasidium pullulans orally administered beta-1,3-1,6-glucan (Nichi GLOW), published in BMJ Neurology Open (http://dx.doi.org/10.1136/bmjno-2021-000203). Beneficial reconstitution of the gut microbiota has also been reported with Nichi GLOW, which is unique due to its source, method of manufacture, and purity from other beta-glucans.

This press release contains multimedia content. See the full announcement here: https://www.businesswire.com/news/home/20220313005032/en/

Improved learning and communication skills, sleep pattern, and sleep quality along with peer interaction were the main changes observed in a clinical study after 90 days of consumption of the dietary supplement Nichi GLOW beta glucan, according to parents of study participants. One of them demonstrated his reading, writing, and math skills at a follow-up visit with Dr. Raghavan, a pediatrician and developmental neurologist. Considered ß-glucans remove aggregated alpha-synuclein by enhancing NK cells and, as a prebiotic, controlling Enterobacteriaceae, one of the causes of disease, thus may have potential to address neurological diseases involving microbiome dysbiosis intestinal. Nichi GLOW, a safe food supplement, which does not contain any allergens, is worth conducting larger clinical studies of longer follow-up in different populations to validate it as an adjunct to conventional treatment in neurodegenerative and neurodevelopmental diseases, and the microbiota also varies with eating habits. Dr. Raghavan said. (Graphic: Business Wire)

Autism is a neurodevelopmental disorder that affects 1 in 44 children in the industrialized world, with multiple causes and varying degrees of severity of manifestation. These children are more likely to develop neurodegenerative diseases in the future. In the study, taking Nichi GLOW improved CARS score and communication skills (https://www.youtube.com/watch?v=reJOjBMKSg4). Enterobacteriaceae controlled by Nichi GLOW, a gut microbiome that produces harmful proteins such as curly and amyloid, leading to misfolding and aggregation of alpha-synuclein in neurons, one of the causes of disease (https://doi.org /10.1101/2021.10.26.21265505). Synucleinopathy, which spreads to the brain via the gut-brain axis, can cause Parkinson’s or dementia, so it’s worth considering investigate the prophylaxis of the Nichi Glucan range of products in neurodegenerative diseases, since the activation of microglia is one of the mechanisms of their action in the brain (https://doi.org/10.1016/j.jns.2021.117554), says Dr. Raghavan, the principal investigator.

The results were presented in a webinar commemorating the autism sunday (https://www.ncrmniche.org/autismsunday2022/proceedings/index.html) organized by the Antonyraj Jesuit Memorial Interdisciplinary Center for Advanced Recovery and Education (JAICARE). Research conducted in Japan revealed the hidden potentials (https://doi.org/10.1101/2021.08.05.21261640) of this ß-glucan; Thanks to a healthy ecosystem in Japan that supports the development of novel solutions, coupled with GN Corp’s global interdisciplinary network of healthcare expertise, have made this groundbreaking achievement possible, the scientists said. https://sponsored.bloomberg.com/article/jco/japan-where-high-tech-meets-high-value-foreign-direct-investment

The Nichi Glucan range of products was approved as a food additive in Japan in 1996 and does not contain any commonly reported allergens. They are unique in that they are exopolysaccharides derived from new strains of Aureobasidium pullulans Manufactured in a GMP certified facility in Japan and exported under various brands: Nichi-GLOW, Neu-REFIX, Nichi Glucan and Nichi Glucan-REFIX they are not intended to diagnose, treat, cure, or prevent any disease and approval status may vary by country. The publications are intended for academic and research initiatives and should not be construed as medical advice. Medical advice is recommended for specific health problems.

The source language in which the original text is published is the official and authorized version. Translations will be included for better understanding. Only the version in the language that was originally published is legally valid. Therefore, compare the translations with the original language version of the publication.

View the original version on businesswire.com: https://www.businesswire.com/news/home/20220313005032/en/

contacts

Samuel J K Abraham
[email protected]

Source link

- Advertisement -

New Articles